New Zealand Cannabis Referendum: History, Results, and Policy Impact

Executive Summary

New Zealand's Parliament passed enabling legislation in June 2026 to establish the procedural framework for a national cannabis referendum, marking the country's second attempt to resolve the question of adult-use legalization through direct democracy. The bill creates the administrative and legal mechanisms necessary for a binding public vote, though it does not set a referendum date or specify the exact question voters will face. This development follows New Zealand's narrow defeat of a cannabis legalization proposal in October 2020, when 50.7% of voters rejected the Cannabis Legalisation and Control Bill during a referendum held alongside the general election. The 2026 parliamentary action reflects sustained advocacy from reform groups, evolving public opinion data showing increased support for regulated access, and pressure from the medicinal cannabis industry for clarity on the recreational market's future. The referendum process bill establishes voter eligibility criteria, campaign finance rules, and the threshold for passage, while leaving substantive policy details—possession limits, retail licensing, taxation rates, and home cultivation provisions—to be determined through subsequent legislation if voters approve legalization. Political observers note the timing positions cannabis policy as a potential election issue, with major parties divided on whether to campaign for or against reform.

Why This Matters

The referendum framework affects 5.1 million New Zealanders and could create a regulated cannabis market worth an estimated NZ$350-450 million annually, while reshaping criminal justice outcomes for approximately 10,000 people arrested each year for cannabis offenses. The stakes extend across multiple stakeholder groups. For patients, the referendum outcome will determine whether the existing Medicinal Cannabis Scheme remains the only legal access pathway or whether a broader adult-use system emerges that could reduce costs and expand product availability. New Zealand's medicinal program, established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, currently serves approximately 35,000 registered patients but faces criticism for high prices—often NZ$400-600 per month—that drive continued black market use. For law enforcement and the justice system, legalization would eliminate the legal basis for the majority of cannabis arrests, which disproportionately affect Māori communities. Ministry of Justice data shows Māori are 2.8 times more likely to be prosecuted for cannabis possession than non-Māori despite similar usage rates, making the referendum a significant criminal justice reform question with racial equity implications. The business community watches closely as international cannabis companies have established medicinal operations in New Zealand anticipating potential adult-use expansion. Companies including Helius Therapeutics, Rua Bioscience, and Cannasouth have invested over NZ$200 million in cultivation facilities and processing infrastructure. A "yes" vote would allow these operators to pivot to recreational production, while a "no" vote would limit their addressable market to the smaller medicinal segment and export opportunities. Tax revenue projections add fiscal significance. Treasury modeling suggests a regulated market could generate NZ$80-150 million in annual excise tax revenue, funds that reform advocates propose directing toward addiction treatment services, mental health programs, and community development in areas disproportionately affected by drug war enforcement.

Background and History

New Zealand's path to a cannabis referendum began with decades of incremental reform, accelerating after the 2017 general election when the Labour-led coalition government committed to holding a public vote on legalization.

Early Decriminalization Debates (1970s-1990s)

Cannabis arrived in New Zealand during the 1960s counterculture movement, and by the 1970s parliamentary debates began addressing enforcement priorities. The Misuse of Drugs Act 1975 established the current classification system, placing cannabis as a Class C controlled drug with maximum penalties of three months imprisonment for possession and eight years for supply. Throughout the 1980s, the New Zealand Drug Foundation and other harm reduction advocates pushed for decriminalization, but conservative governments maintained prohibition policies. A 1998 parliamentary health committee inquiry examined cannabis policy and recommended reducing penalties for personal possession, but the National Party government declined to implement the changes. The early 2000s saw increased enforcement, with annual cannabis arrests peaking at approximately 18,000 in 2009.

Medicinal Cannabis Movement (2000s-2017)

Public pressure for medicinal access intensified following high-profile cases of patients using cannabis to manage chronic pain and chemotherapy side effects. In 2017, the case of Alex Renton, a 19-year-old with severe epilepsy whose family sought access to CBD oil, catalyzed national debate. Associate Health Minister Peter Dunne fast-tracked regulatory changes allowing CBD products with less than 2% THC to be prescribed, though access remained limited. The 2017 general election brought a Labour-Green-New Zealand First coalition to power, with the confidence and supply agreement including a commitment to hold a referendum on cannabis legalization during the 2020 election cycle. Prime Minister Jacinda Ardern tasked a working group with developing a legislative framework for voters to consider.

The 2020 Referendum Campaign

The Cannabis Legalisation and Control Bill was released in draft form in July 2019, proposing a regulated market for adults 20 and older with a 14-gram purchase limit, licensed retail stores, home cultivation of two plants per person (four per household), and a ban on edibles for the first two years. The bill proposed establishing a Cannabis Regulatory Authority modeled on New Zealand's alcohol licensing system. The referendum question asked: "Do you support the proposed Cannabis Legalisation and Control Bill?" Voting occurred alongside the October 17, 2020 general election, with results announced on November 6, 2020. The measure failed narrowly: 50.7% voted "no" and 48.4% voted "yes," with 0.9% of ballots informal. Turnout reached 83% of enrolled voters. Analysis of voting patterns revealed strong urban-rural divides. Wellington and Auckland showed majority support (53% and 51% respectively), while rural electorates and smaller cities voted decisively against legalization. Age demographics played a significant role: voters under 35 supported legalization at approximately 65%, while those over 65 opposed it at similar rates.

Post-Referendum Developments (2021-2025)

Despite the referendum defeat, cannabis policy remained politically active. In 2021, Parliament passed amendments to the Misuse of Drugs Act reducing penalties for possession of small amounts, making first-time possession of up to 14 grams subject to police discretion for warnings rather than automatic prosecution. The change reduced arrest numbers but did not eliminate criminal liability. The medicinal cannabis market expanded significantly between 2020 and 2025. The number of licensed cultivators grew from three to twelve, and the Ministry of Health approved over 100 medicinal cannabis products for prescription. However, patient advocates continued criticizing high costs and limited product diversity compared to mature markets like Canada and several U.S. states. Public opinion polling showed shifting attitudes. A December 2023 Horizon Research poll found 54% support for legalization, up from the 48.4% referendum result. A February 2025 Curia Market Research survey reported 57% support, with particularly strong increases among voters aged 35-50. Reform advocates attributed the shift to normalization of medicinal use, evidence from jurisdictions that legalized after 2020, and generational replacement as older opponents aged out of the electorate.

The 2026 Parliamentary Bill

In March 2026, Green Party MP Chlöe Swarbrick introduced a member's bill establishing the procedural framework for a cannabis referendum. The Cannabis Referendum Enabling Act 2026 passed its first reading with support from Labour, the Greens, and the Māori Party, while National and ACT opposed. The bill underwent select committee review with public submissions, receiving over 8,000 written submissions—approximately 70% in favor of enabling the referendum process. The legislation passed its third reading on June 19, 2026, with a 68-53 vote. The Act establishes that any future cannabis referendum will require a simple majority to pass, sets campaign spending limits at NZ$4 million per side, and requires the Electoral Commission to conduct public education about the referendum question. Critically, the bill does not schedule a referendum date or specify the substantive policy question, leaving those decisions to future parliamentary action or coalition negotiations following the next general election.

Key Players

Electoral Commission

The Electoral Commission holds responsibility for administering any cannabis referendum under the 2026 enabling legislation. The Commission will develop the official wording of the referendum question, manage voter registration, oversee campaign finance compliance, and conduct the vote count. Chief Electoral Officer Karl Le Quesne said the Commission has begun preliminary planning for potential referendum administration, though no date has been set.

Ministry of Health

The Ministry of Health administers the current Medicinal Cannabis Scheme and would play a central role in implementing any adult-use legalization framework. The Ministry's regulatory experience with medicinal licensing, product standards, and quality control would inform the structure of a recreational regulatory authority. Director-General of Health Dr. Diana Sarfati has emphasized that any legalization framework must include robust public health protections, particularly for youth access prevention and impaired driving enforcement.

New Zealand Drug Foundation

The New Zealand Drug Foundation, led by Executive Director Sarah Helm, has advocated for cannabis law reform for over two decades. The Foundation supported the 2020 referendum and has continued campaigning for a health-based approach to drug policy. The organization has published research on tax revenue projections, criminal justice impacts, and regulatory models, positioning itself as a key technical resource for policymakers and the public.

Make It 16

Make It 16, the youth-led advocacy group that successfully lowered the voting age to 16 in local elections, has engaged in cannabis policy debates from a youth rights and harm reduction perspective. The organization argues that prohibition has failed to prevent youth access and that regulated markets with strict age verification provide better protection than uncontrolled black markets.

Family First New Zealand

Family First New Zealand, a conservative advocacy organization led by Bob McCoskrie, actively opposed the 2020 referendum and continues campaigning against legalization. The group emphasizes concerns about youth mental health impacts, impaired driving risks, and normalization of drug use. Family First has indicated it will mount a vigorous "no" campaign if another referendum is scheduled.

Helius Therapeutics and Rua Bioscience

Helius Therapeutics and Rua Bioscience represent the two largest medicinal cannabis cultivators in New Zealand. Both companies hold licenses under the Medicinal Cannabis Scheme and have invested in large-scale indoor and outdoor cultivation facilities. Helius operates a 5,000-square-meter indoor facility in Christchurch, while Rua Bioscience cultivates on 1.2 hectares in Gisborne. Both companies have publicly stated they are prepared to transition to adult-use production if legalization passes, though they have avoided taking public positions on the referendum itself to maintain relationships with medicinal patients and prescribers across the political spectrum.

New Zealand Police

The New Zealand Police enforces current cannabis prohibition and would see significant operational changes under legalization. Police Commissioner Andrew Coster has maintained institutional neutrality on legalization policy while noting that cannabis enforcement consumes substantial resources that could be redirected to other priorities. Police data shows cannabis offenses account for approximately 40% of all drug arrests, with enforcement concentrated in lower-income communities.

Māori Health Authority

The Māori Health Authority, established in 2022 to address health inequities, has examined cannabis policy through a Treaty of Waitangi lens. The Authority has noted that Māori experience disproportionate harm from prohibition enforcement while also expressing concerns about commercial cannabis markets potentially exploiting Māori communities. The Authority has called for any legalization framework to include Māori governance participation, equitable licensing opportunities, and revenue sharing for Māori health and social services.

Legal and Regulatory Framework

New Zealand's cannabis legal structure rests on the Misuse of Drugs Act 1975, which classifies cannabis as a Class C controlled drug, while the 2018 medicinal amendments and 2026 referendum enabling legislation create parallel pathways for regulated access and democratic decision-making. The Misuse of Drugs Act 1975 remains the foundational statute. Section 7 prohibits possession of any Class C controlled drug, with cannabis specifically listed in Schedule 3. Maximum penalties include three months imprisonment or a NZ$500 fine for possession, and eight years imprisonment for supply or cultivation. Section 7A, added in 2019, provides police discretion to issue warnings for first-time possession of up to 14 grams rather than proceeding with prosecution, though this remains a discretionary rather than mandatory diversion. The Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 created a parallel legal framework for medicinal access. The Act established the Medicinal Cannabis Scheme, which allows licensed cultivators to produce cannabis for medicinal purposes and permits doctors to prescribe approved cannabis products. Regulations under the Act set minimum quality standards, including testing for contaminants and potency verification, and created a product approval pathway through the Ministry of Health. As of June 2026, twelve companies hold cultivation licenses and 127 products have received approval for prescription. The Medicinal Cannabis Agency, operating within the Ministry of Health, administers licensing and compliance. The Agency conducts facility inspections, reviews product applications, and maintains the register of approved medicinal cannabis products. Patients access medicinal cannabis through prescriptions from registered medical practitioners, though the products are not subsidized under the Pharmaceutical Management Agency (PHARMAC) formulary, resulting in out-of-pocket costs. The Cannabis Referendum Enabling Act 2026 establishes the procedural framework for conducting a binding referendum on adult-use legalization. The Act specifies that the Electoral Commission will administer the referendum, sets campaign spending limits at NZ$4 million per registered campaign group, and requires a simple majority (50% plus one vote) for passage. The Act mandates that the referendum question must clearly describe the proposed policy change and that the Electoral Commission must conduct public education about the proposal's contents. Critically, the 2026 Act does not itself legalize cannabis or specify the substantive policy that voters would approve. Instead, it creates the mechanism for a future referendum, with the actual policy proposal to be developed through subsequent legislation. This approach differs from the 2020 referendum, where the Cannabis Legalisation and Control Bill was drafted in advance and voters knew the specific regulatory framework they were approving or rejecting. Treaty of Waitangi considerations intersect with cannabis policy. The Treaty, New Zealand's founding document establishing partnership between the Crown and Māori, requires the government to actively protect Māori interests and ensure equitable outcomes. Legal scholars have argued that any cannabis legalization framework must address the disproportionate enforcement harm Māori have experienced under prohibition and ensure Māori participation in the legal market through licensing preferences or reserved allocations. The Waitangi Tribunal has not yet issued a formal finding on cannabis policy, but the Māori Health Authority has invoked Treaty principles in its policy submissions. International treaty obligations also constrain New Zealand's options. New Zealand is party to the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs. These treaties require signatories to limit cannabis to medical and scientific purposes. However, Canada's 2018 legalization and Uruguay's 2013 legalization occurred without those countries withdrawing from the treaties, instead interpreting their obligations as permitting domestic regulatory discretion. New Zealand could adopt a similar interpretive approach, though it would face potential criticism from the International Narcotics Control Board.

Market and Business Implications

A successful referendum could create a legal cannabis market generating NZ$350-450 million in annual sales, transforming existing medicinal operators into multi-market businesses while attracting new capital from domestic and international investors. The current medicinal market provides a baseline for projecting adult-use scale. Industry analysts estimate the medicinal market reached approximately NZ$60 million in sales during 2025, serving roughly 35,000 registered patients. By contrast, adult-use legalization would open access to New Zealand's estimated 400,000-500,000 current cannabis consumers, the majority of whom currently purchase from the illicit market. Economic modeling by the New Zealand Institute of Economic Research (NZIER) projects that a mature legal market would capture 60-70% of current illicit demand within three years of legalization, with full market maturation taking five to seven years. The NZIER model assumes average retail prices of NZ$15-18 per gram, lower than current black market prices of NZ$20-25 per gram but higher than wholesale costs due to excise taxes and regulatory compliance expenses. Existing medicinal cannabis companies hold significant competitive advantages for adult-use entry. Helius Therapeutics, Rua Bioscience, and other licensed cultivators have already navigated the regulatory approval process, established quality control systems, and built relationships with government agencies. These companies could rapidly scale production by expanding existing facilities or converting medicinal capacity to recreational production. Helius CEO Gary Lyford told the New Zealand Herald in April 2026 that the company has designed its Christchurch facility with modular expansion capability that could triple output within 18 months if legalization passes. However, the licensing framework for adult-use sales remains undefined. The failed 2020 Cannabis Legalisation and Control Bill proposed a competitive licensing system with no caps on the number of retail licenses, similar to New Zealand's approach to alcohol retail. Alternative models could include limited licensing with geographic restrictions, social equity provisions reserving licenses for communities harmed by prohibition, or a government monopoly retail system similar to New Zealand's approach to alcohol sales in some regions historically. Tax structure will significantly impact market dynamics. The 2020 bill proposed a 10% excise tax on wholesale value plus standard 15% Goods and Services Tax (GST) on retail sales. Treasury modeling suggested this would generate NZ$80-150 million annually at market maturity. However, tax rates must balance revenue generation against undercutting the illicit market—excessive taxation in California and Canada has allowed black markets to persist by making legal products significantly more expensive than illegal alternatives. Employment projections suggest the legal market could create 2,500-4,000 direct jobs in cultivation, processing, retail, and testing, plus additional indirect employment in security, legal services, and ancillary businesses. The New Zealand Council of Trade Unions has called for any legalization framework to include labor standards ensuring living wages and safe working conditions, noting that cannabis industry workers in some U.S. states face workplace safety issues and union-busting. Banking and financial services present ongoing challenges. While New Zealand banks are not subject to the same federal prohibition constraints as U.S. banks, financial institutions have expressed caution about serving cannabis businesses due to anti-money laundering compliance concerns and international correspondent banking relationships. The Reserve Bank of New Zealand has indicated it would issue guidance to banks on cannabis business accounts if legalization passes, but has not committed to requiring banks to serve the industry. International trade opportunities exist but face constraints. New Zealand could export medicinal cannabis to countries with legal medicinal programs, and several licensed cultivators have pursued export strategies. However, adult-use exports would be limited to jurisdictions that have also legalized recreational use—currently only Canada, Uruguay, and a small number of other countries. The Trans-Pacific Partnership and other trade agreements do not require New Zealand to allow cannabis imports, giving the government discretion to protect domestic producers.

What Experts Say

Public health researchers, economists, and legal scholars have offered divergent assessments of cannabis legalization's likely impacts, with debate centering on youth access, mental health effects, criminal justice outcomes, and regulatory design. Dr. Joseph Boden, a professor at the University of Otago's Christchurch Health and Development Study, has published longitudinal research on cannabis use and mental health outcomes. According to his research findings, frequent cannabis use during adolescence correlates with increased risk of psychotic symptoms and depression in early adulthood, though causation remains difficult to establish definitively. Boden has stated that any legalization framework must include robust age restrictions and public education about risks for young users, while noting that prohibition has not prevented youth access. Professor Chris Wilkins, who directs the SHORE and Whariki Research Centre at Massey University, has studied New Zealand's illicit cannabis market for over 15 years. According to Wilkins, the current black market generates approximately NZ$400 million in annual revenue with no quality control, no age verification, and no tax contribution. Wilkins has argued that regulation would improve public health outcomes by creating product testing requirements, reducing synthetic cannabinoid availability, and funding treatment services through tax revenue. Dr. Rawiri Waretini, a Māori health researcher at the University of Waikato, has examined cannabis policy through an indigenous health equity lens. According to Waretini, prohibition has functioned as a tool of systemic racism, with Māori experiencing disproportionate arrest rates and criminal justice involvement for behavior that occurs at similar rates across ethnic groups. Waretini has called for any legalization framework to include restorative justice provisions, such as expungement of prior cannabis convictions and preferential licensing for Māori-owned businesses. Economist Shamubeel Eaqub, a principal at Sense Partners, has analyzed the fiscal and economic impacts of legalization. According to Eaqub's modeling, a legal market would generate NZ$80-150 million in annual tax revenue while reducing criminal justice system costs by approximately NZ$30-40 million through decreased arrests, prosecutions, and incarceration. Eaqub has noted that revenue projections depend heavily on tax rates and regulatory costs—excessive compliance burdens could prevent legal businesses from competing with the illicit market. Dr. Simon Denny, an addiction medicine specialist and former president of the New Zealand Medical Association, has expressed concerns about commercialization and marketing. According to Denny, the alcohol and tobacco industries demonstrate that commercial interests prioritize profit maximization over public health, leading to aggressive marketing and product innovation designed to increase consumption. Denny has advocated for a non-commercial model such as government-operated retail or non-profit cooperatives if legalization proceeds. Legal scholar Professor Andrew Geddis at the University of Otago has analyzed the constitutional and democratic dimensions of the referendum process. According to Geddis, binding referendums create tension with New Zealand's parliamentary sovereignty tradition, where Parliament retains ultimate legislative authority. The 2026 enabling legislation's decision to separate the procedural framework from the substantive policy question addresses this tension by preserving Parliament's role in crafting the actual legalization bill, while committing to respect the referendum outcome.

What's Next

The referendum's timing and the substantive policy question voters will consider remain undecided, with the next general election cycle and coalition negotiations likely determining when New Zealanders vote on cannabis legalization. New Zealand's next general election must occur by November 2026, though Prime Minister Christopher Luxon has not announced a specific date. Political analysts expect the election in September or October 2026. Cannabis policy could feature in coalition negotiations if no party wins an outright majority, as occurred in 2017 when the referendum commitment emerged from Labour-Green-New Zealand First negotiations. The Green Party has indicated it will campaign on holding a cannabis referendum during the 2026-2029 parliamentary term, potentially in 2027 or 2028. Labour has not committed to a specific timeline but has expressed openness to revisiting the question given polling showing increased public support since 2020. National and ACT oppose holding another referendum, arguing that the 2020 vote settled the question. If a referendum is scheduled, the Electoral Commission would require approximately 12-18 months lead time to develop the question wording, establish campaign finance registration, and conduct public education. This timeline suggests that a referendum held during the 2026-2029 term would likely occur no earlier than mid-2027. The substantive policy framework voters would approve remains to be determined. Options include reintroducing the 2020 Cannabis Legalisation and Control Bill with modifications, developing an entirely new legislative proposal, or asking voters a principle-level question about whether to legalize with details to be determined by Parliament afterward. Reform advocates have argued for incorporating lessons from jurisdictions that legalized after 2020, including social equity licensing provisions, lower tax rates to compete with illicit markets, and allowance for edibles and other product forms from the outset. Legal challenges could emerge regardless of the referendum outcome. If legalization passes, opponents might challenge the implementing legislation on Treaty of Waitangi grounds if Māori interests are not adequately protected, or on public health grounds arguing inadequate youth protections. If legalization fails again, reform advocates might pursue incremental changes such as expanded decriminalization or home cultivation allowances through normal legislative processes. International developments will continue influencing New Zealand's debate. Germany implemented adult-use legalization in April 2024, providing a European model for regulation. Australia's states are considering various reform proposals, with the Australian Capital Territory having decriminalized possession and home cultivation in 2020. Thailand legalized cannabis in 2022 but faced implementation challenges and political backlash, providing cautionary lessons about regulatory design. The medicinal market will continue expanding regardless of referendum outcomes. The Ministry of Health has signaled openness to approving additional product types and streamlining prescription processes, potentially reducing costs and improving access for patients. However, medicinal advocates argue that adult-use legalization would create economies of scale that would benefit medicinal patients through lower prices and greater product diversity.

Further Reading

• Misuse of Drugs Act 1975 (full text): https://www.legislation.govt.nz/act/public/1975/0116/latest/DLM436100.html
• Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018: https://www.legislation.govt.nz/act/public/2018/0053/latest/whole.html
• Cannabis Referendum Enabling Act 2026: https://www.legislation.govt.nz/act/public/2026/0024/latest/whole.html
• Electoral Commission 2020 Cannabis Referendum Results: https://www.electionresults.govt.nz/electionresults_2020/referendum.html
• Ministry of Health Medicinal Cannabis Scheme: https://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicinal-cannabis-agency
• New Zealand Drug Foundation Cannabis Policy Resources: https://www.drugfoundation.org.nz/policy-and-advocacy/cannabis/
• NZIER Economic Impact Assessment (2019): https://nzier.org.nz/publication/the-economic-impacts-of-cannabis-legalisation-in-new-zealand
• University of Otago Christchurch Health and Development Study: https://www.otago.ac.nz/christchurch/research/healthdevelopment/
• Waitangi Tribunal: https://waitangitribunal.govt.nz/
• New Zealand Police Drug Harm Index: https://www.police.govt.nz/about-us/publications-statistics/data-and-statistics/policedatanzgovtnz